Less toxic chemotherapy for soft tissue sarcomas

A recent study comparing standard regimens of doxorubicin and ifosfamide vs gemcitabine(G) and docetaxel(D) showed positive trends with the less toxic GD regimen.  There was a trend towards fewer hospitalizations from side effects of treatment and also a trend to longer disease free survival (DFS) for patients who received GD regimen.  More works needs to be done to see if this is the best option for the high-risk patient.  Only 80 patients were evaluated between 2004 and 2012.  To read more go to the complete reference below:
Eur J Cancer. 2015 Sep;51(13):1794-802.

A randomised, open-label, phase II study of neo/adjuvant doxorubicin and ifosfamide versus gemcitabine and docetaxel in patients with localised, high-risk, soft tissue sarcoma.

Subscribe To Our Newsletter

Enter your email below to join our mailing list.